Targeting Clonal Heterogeneity In Treatment-Refractory GBM With Empiric Polytherapy

Time: 4:10 pm


  • Review the biological profile of treatment-refractory glioblastoma
  • Explore the application of an integrative multi-omics target discovery platform for human GBM which incorporates DNA cellular barcoding, glycocapture profiling of the cell surface proteome, RNA sequencing, single-cell sequencing and genome-wide CRISPR screening of primary and recurrent GBM
  • Review the rationale for combinatorial polytherapy for targeting intratumoral heterogeneity and therapy-driven clonal evolution found in GBM recurrence